Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

ConclusionsThis model confirms the Bellmunt model with the addition of NLR  >  3 and GFR less than 60 ml/min and can be associated with clinical trials that use immunotherapy in patients with bladder cancer.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research